News
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
NanoViricides, Inc. signs MSA with regulatory consultant firm for orphan drug strategy development for NV-387, a broad-spectrum antiviral with potential against Smallpox, Measles, and more -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. files Form 10-Q for Q3 2025 with SEC, presents NV-387 as broad-spectrum antiviral drug addressing unmet medical needs. Company strengthens financial position with recent financings -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NanoViricides, Inc. to present NV-387, a revolutionary broad-spectrum antiviral drug, at Pharma Partnering Summit 2025. NV-387 mimics virus features to combat viral infections effectively -
